Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
233 results about "Pyrimidine Nucleotides" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Nucleic acids then are polymeric macromolecules assembled from nucleotides, the monomer-units of nucleic acids. The purine bases adenine and guanine and pyrimidine base cytosine occur in both DNA and RNA, while the pyrimidine bases thymine (in DNA) and uracil (in RNA) in just one.
Recombinant binding proteins and peptides
DNA constructs comprise a first exon sequence of nucleotides encoding a first peptide or polypeptide, a second exon sequence of nucleotides encoding a second peptide or polypeptide and a third sequence of nucleotides between the first and second sequences encoding a heterologous intron, for example that of Tetrahymena thermophila nuclear pre-rRNA, between RNA splice sites and a site-specific recombination sequence, such as loxP, within the intron, the exons together encoding a product peptide or polypeptide. Such constructs are of use in methods of production of peptides or polypeptides, transcription leading to splicing out of the intron enabling translation of a single chain product peptide or polypeptide. Isolated nucleic acid constructs consisting essentially of a sequence of nucleotides encoding a self-splicing intron with a site-specific recombination sequence within the intron, for use in creation of constructs for expression of peptides or polypeptides, are also provided.
Owner:MEDICAL RESEARCH COUNCIL
mRNA cap analogs
ActiveUS8519110B2Wide range of usesImprove stabilitySugar derivativesMetabolism disorderPhosphateIn vivo
Dinucleotide cap analogs are disclosed, modified at different phosphate positions with a boranophosphate group or a phosphoroselenoate group. The analogs are useful as reagents in the preparation of capped mRNAs and have increased stability both in vitro and in vivo. They may be used as inhibitors of cap-dependent translation. Optionally, the boranophosphate or phosphoroselenoate group has a 2′-O or 3′-O-alkyl group, preferably a methyl group, producing analogs called BH3-ARCAs or Se-ARCAs. ARCAs may be modified with α-, β-, or γ-boranophosphate or phosphoroselenoate groups.
Owner:UNIWERSYTET WARSZAWSKI +1
Compositions and methods for activating stimulator of interferon gene-dependent signalling
The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are substantially pure 2′,5′,2′,5′ and 2′,5′,3′,5′ CDNs, and preferably Rp,Rp stereosiomers thereof.
Owner:RGT UNIV OF CALIFORNIA +1
Immunomodulatory oligonucleotides
Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides that do not contain unmethylated CpG sequences (i.e. methylated CpG sequences or no CpG sequence) to outcompete unmethylated CpG nucleic acids for binding. Further disclosed are methylated CpG containing dinucleotides for use antisense therapies or as in vivo hybridization probes, and immunoinhibitory oligonucleotides for use as antiviral therapeutics.
Owner:IOWA RES FOUND UNIV OF +3
High-throughput methods for detecting DNA methylation
InactiveUS6605432B1Bioreactor/fermenter combinationsBiological substance pretreatmentsDNA methylationHybridization probe
Owner:UNIVERSITY OF MISSOURI
Immunomodulatory oligonucleotides
InactiveUS20050004062A1Improve responseIncrease the number ofOrganic active ingredientsSugar derivativesHybridization probeIn vivo
Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides that do not contain unmethylated CpG sequences (i.e. methylated CpG sequences or no CpG sequence) to outcompete unmethylated CpG nucleic acids for binding. Further disclosed are methylated CpG containing dinucleotides for use antisense therapies or as in vivo hybridization probes, and immunoinhibitory oligonucleotides for use as antiviral therapeutics.
Owner:COLEY PHARM GRP INC +1
Methods for treating and preventing infectious disease
InactiveUS20050101554A1High sensitivityAntibacterial agentsGenetic material ingredientsAdjuvantNucleic acid sequencing
Nucleic acid sequences containing unmethylated CpG dinucleotides that modulate an immune response including stimulating a Th1 pattern of immune activation, cytokine production, NK lytic activity, and B cell proliferation are disclosed. The sequences are also useful as a synthetic adjuvant.
Owner:UNIV OF IOWA RES FOUND +2
Cyclic-Dinucleotides and Its Conjugates as Adjuvants and Their Uses in Pharmaceutical Compositions
ActiveUS20080286296A1Severe formLess immunomodulatory effectOrganic active ingredientsAntipyreticDiseaseAutoimmune responses
The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new compounds useful as adjuvants and / or immunomodulators for prophylactic and / or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumors, allergies as well as for the control of fertility in human or animal populations. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants. In addition, the invention relates to its uses as active ingredients in pharmaceutical compositions.
Owner:GESELLSCHAFT FUR BIOTECHNOLOGISCHE FORSCHUNG MBH GBF
Immunostimulatory nucleic acid molecules for activating dendritic cells
InactiveUS20070065467A1Th responseEffective adjuvantOrganic active ingredientsSugar derivativesDendritic cellPyrimidine Nucleotides
Owner:UNIV OF IOWA RES FOUND
Dinucleotide MRNA cap analogs
ActiveUS8304529B2Increase opportunitiesImprove translationSugar derivativesActivity regulationPyrimidine NucleotidesRibose
Owner:APPL BIOSYSTEMS INC
Method for stimulating the immune, inflammatory or neuroprotective response
Owner:KARAGEN PHARMA INC +1
Compositions and methods for inhibiting "stimulator of interferon gene" -dependent signalling
ActiveUS20140341976A1Suppress overreactionOrganic active ingredientsSugar derivativesPurineStimulator of interferon genes
The present invention provides cyclic-di-nucleotide (CDN) compounds that inhibit signaling at a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides which inhibit STING-dependent TBK1 activation and the resulting production of type I interferon.
Owner:ADURO BIOTECH
Method of inducing an antigen-specific immune response by administering a synergistic combination of adjuvants comprising unmethylated CpG-containing nucleic acids and a non-nucleic acid adjuvant
The present invention relates generally to adjuvants, and in particular to methods and products utilizing a synergistic combination of immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) and a non-nucleic acid adjuvant. Such combinations of adjuvants may be used with an antigen or alone. The present invention also relates to methods and products utilizing immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) for induction of cellular immunity in infants.
Owner:UNIV OF IOWA RES FOUND +2
Locked nucleic acid containing heteropolymers and related methods
InactiveUS7053195B1Increasing accessibility and exposurePromote rapid formationSugar derivativesNucleic acid sequencingA-DNA
The present invention relates to methods of replacing nucleotides in target nucleic acid sequences using DNA-LNA chimeras. The method of the present invention provides for replacing a first nucleotide in a target sequence by exposing the target sequence to a DNA-LNA heteropolymer and thereby replacing the first nucleotide with a second nucleotide. The invention also features the DNA-LNA chimeras themselves as well as methods of making them.
Owner:SYNGENTA PARTICIPATIONS AG
Immunostimulatory nucleic acid molecules
Owner:UNIV OF IOWA RES FOUND +2
Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
ActiveUS20140205653A1Suppress overreactionOrganic active ingredientsBacterial antigen ingredientsEnantiomerPurine
It is an object of the present invention to provide novel and highly active cyclic-di-nucleotide (CDN) immune stimulators that activates DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides that induce STING-dependent TBK1 activation, wherein the cyclic purine dinuclotides present in the composition are substantially pure Rp,Rp or Rp,Sp stereoisomers, and particularly substantially pure Rp,Rp, or RpSp CDN thiophosphate diastereomers.
Owner:CHINOOK THERAPEUTICS INC
High-throughput methods for detecting DNA methylation
InactiveUS20030129602A1Bioreactor/fermenter combinationsBiological substance pretreatmentsDNA methylationHybridization probe
The present invention provides a method of hybridization, differential methylation hybridization (DMH) for high throughput methylation analysis of multiple CpG island loci. DMH utilizes nucleic acid probes prepared from a cell sample to screen numerous CpG dinucleotide rich fragments affixed on a screening array. Positive hybridization signals indicate the presence of methylated sites. Methods of preparing the hybridization probes and screening array are also provided.
Owner:UNIVERSITY OF MISSOURI
Dinucleotide MRNA CAP Analogs
ActiveUS20100261231A1Increase opportunitiesImprove translationSugar derivativesActivity regulationRibosePyrimidine Nucleotides
Novel cap analogs which are easily synthesized, resulting in high levels of capping efficiency and transcription and improved translation efficiencies are provided. Such caps are methylated at the N7 position of one or both guanosines of the dinucleotide cap as well as at the 3′ position on the ribose ring. Substituent groups on the ribose ring also result in the cap being incorporated in the forward orientation. Also provided are methods useful for preparing capped analogs and using mRNA species containing such analogs are also contemplated herein, as well as kits containing the novel cap analogs.
Owner:APPL BIOSYSTEMS INC
Composition and method for inhibiting platelet aggregation
The present invention provides novel compounds of dinucleotide polyphosphates and the method of preventing or treating diseases or conditions associated with platelet aggregation. The method comprises administering systemically to a patient a pharmaceutical comprising a purinergic P2τ receptor antagonist, in an amount effective to elevate its extracellular concentration to bind to P2τ receptors and inhibit P2τ receptor-mediated platelet aggregation. Methods of systemic administration include injection by intravenous, intramuscular, intrasternal and intravitreal routes, infusion, transdermal administration, oral administration, rectal administration and intra-operative instillation.
Owner:INSPIRE PHARMA +1
Method for stimulating the immune, inflammatory or neuroprotective response
Owner:KARAGEN PHARMA INC
Detection of methylated CpG rich sequences diagnostic for malignant cells
InactiveUS6893820B1Microbiological testing/measurementMaterial analysis by electric/magnetic meansAbnormal tissue growthCancer cell
The present invention provides methods for determining the methylation status of CpG-containing dinucleotides on a genome-wide scale using infrequent cleaving, methylation sensitive restriction endonucleases and two-dimensional gel electrophoretic display of the resulting DNA fragments. Such methods can be used to diagnose cancer, classify tumors and provide prognoses for cancer patients. The present invention also provides isolated polynucleotides and oligonucleotides comprising CpG dinucleotides that are differentially methylated in malignant cells as compared to normal, non-malignant cells. Such polynucleotides and oligonucleotides are useful for diagnosis of cancer. The present invention also provides methods for identifying new DNA clones within a library that contain specific CpG dinucleotides that are differentially methylated in cancer cells as compared to normal cells.
Owner:THE OHIO STATE UNIV RES FOUND
Immunostimulatory nucleic acid molecules
InactiveUS20050182017A1High sensitivityAntibacterial agentsGenetic material ingredientsAdjuvantNucleic acid sequencing
Nucleic acid sequences containing unmethylated CpG dinucleotides that modulate an immune response including stimulating a Th1 pattern of immune activation, cytokine production, NK lytic activity, and B cell proliferation are disclosed. The sequences are also useful as a synthetic adjuvant.
Owner:UNIV OF IOWA RES FOUND
Certain dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
The present invention relates to certain novel dinucleotides and formulations thereof which are highly selective agonists of the P2Y2 and / or P2Y4 purinergic receptor. They are useful in the treatment of chronic obstructive pulmonary diseases such as chronic bronchitis, PCD, cystic fibrosis, as well as prevention of pneumonia due to immobility. Furthermore, because of their general ability to clear retained mucus secretions and stimulate ciliary beat frequency, the compounds of the present invention are also useful in the treatment of sinusitis, otitis media and nasolacrimal duct obstruction. They are also useful for treatment of dry eye disease and retinal detachment as well as facilitating sputum induction and expectoration.
Owner:MERCK SHARP & DOHME CORP
Immunostimulatory nucleic acid molecules
InactiveUS7524828B2High sensitivityAntibacterial agentsOrganic active ingredientsAdjuvantNucleic acid sequencing
Owner:UNIV OF IOWA RES FOUND
Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
Owner:ADURO BIOTECH
Method for modulating gene expression by modifying the cpg content
ActiveUS20090324546A1Increasing and reducing numberGene expression is promoted and inhibitedBiocideOrganic active ingredientsRegulator genePyrimidine Nucleotides
The invention relates to nucleic acid modifications for a directed expression modulation by the targeted insertion or removal of CpG dinucleotides. The invention also relates to modified nucleic acids and expression vectors.
Owner:GENEART
CPG-like nucleic acids and methods of use thereof
InactiveUS20080226649A1Enhancing neutrophil proliferationOrganic active ingredientsSugar derivativesAllergyPurine
Immunostimulatory compositions described as CpG-like nucleic acids are provided, including nucleic acids having immunostimulatory characteristics of CpG nucleic acid, despite certain substitutions of C, G, or C and G of the CpG dinucleotide. The substitutions can include, among others, exchange of methylated C for C, inosine for G, and ZpY for CpG, where Z is cytosine or dSpacer and Y is inosine, 2-aminopurine, nebularine, or dSpacer. Also provided are methods for inducing an immune response in a subject using the CpG-like nucleic acids. The methods are useful in the treatment of a subject that has or is at risk of developing an infectious disease, allergy, asthma, cancer, anemia, thrombocytopenia, or neutropenia.
Owner:COLEY PHARMA GMBH
Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
InactiveUS7176296B2Decreasing immunostimulatory effectEnhance immune stimulationUltrasonic/sonic/infrasonic diagnosticsSugar derivativesImmune StimulationPyrimidine Nucleotides
Owner:IDERA PHARMA INC
Compositions and methods for treatment of mitochondrial diseases
InactiveUS20010005719A1Increase resistanceAvoid Cutting InjuriesBiocideSenses disorderDiseaseMitochondrial disease
Compounds, compositions, and methods are provided for treatment of disorders related to mitochondrial dysfunction. The methods comprise administering to a mammal a composition containing pyrimidine nucleotide precursors in amounts sufficient to treat symptoms resulting from mitochondrial respiratory chain deficiencies.
Owner:WELLSTAT THERAPEUTICS
Immunomodulatory oligonucleotides
Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides that do not contain unmethylated CpG sequences (i.e. methylated CpG sequences or no CpG sequence) to outcompete unmethylated CpG nucleic acids for binding. Further disclosed are methylated CpG containing dinucleotides for use antisense therapies or as in vivo hybridization probes, and immunoinhibitory oligonucleotides for use as antiviral therapeutics.
Owner:UNIV OF IOWA RES FOUND +2
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com